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Abstract: Lepidium meyenii (Walp.), commonly called 
maca, is an Andean crop belonging to the Brassicaceae 
family. Maca hypocotils are habitually consumed as cus-
tomary food as well as traditional remedies for pathological 
conditions such as infertility. Moreover, the characteriza-
tion of maca extracts revealed the presence of compounds 
that are able to modulate the nervous system. Aimed to 
evaluate the efficacy of L. meyenii in persistent pain, the 
present study analyzed the effects of a commercial root 
extract from maca in different animal models reproducing 
the most common causes of chronic painful pathologies. A 
qualitative characterization of this commercial extract by 
high performance liquid chromatography-mass spectro-
metry and tandem mass spectrometry analyses allowed us 
to confirm the presence of some macamides known as bio-
active constituents of this root and the absence of the main 
aromatic glucosinolates. The acute oral administration of 
maca extract is able to reduce mechanical hypersensitiv-
ity and postural unbalance induced by the intra-articular 
injection of monoiodoacetate and the chronic-constriction 
injury of the sciatic nerve. Furthermore, L. meyenii extract 
reverts pain threshold alterations evoked by oxaliplatin 
and paclitaxel. A good safety profile in mice and rats was 
shown. In conclusion, the present maca extract could be 
considered as a therapeutic opportunity to relieve articular 
and neuropathic pain.
Keywords: arthritis; Lepidium meyenii; macamide; neu-
ropathy; persistent pain.
1   Introduction
Persistent pain is defined as pain lasting for a period of 
6  months or more. Primary care settings in Asia, Africa, 
Europe, and in the Americas had patients reporting per-
sistent pain in approximately a quarter of the population 
[1]. Arthritis-related diseases, nerve trauma or compres-
sion, and neuropathies induced by metabolic syndromes 
or neurotoxic drugs are among the most common causes 
of persistent pain. Clinical evidence of neuropathic or 
inflammatory pain are hyperalgesia, thermal allodynia 
and spontaneous pain [2]. The choice of therapy depends 
on the type of pain, its intensity, and how the patient 
responds to treatment. Drug therapy, however, continues 
to be inadequate to completely control persistent pain [3]. 
In this context, plant-derived products characterized by 
a safety profile (especially those used as food) emerge as 
interesting resources for individuating novel therapeutic 
possibilities to manage chronic pain.
Maca (Lepidium meyenii Walp.) is a traditional 
Andean crop belonging to the Brassicaceae family and 
it is traditionally used for its nutritional and medicinal 
properties [4]. Maca’s hypocotils are usually consumed 
fresh or dehydrated after boiling in water or milk, after 
being made into juices, maca coffee, or alcoholic bev-
erages [5, 6]. The tubers of L. meyenii have been widely 
investigated during these last years, pointing out the 
copresence of two main groups of phytochemicals, 
the  glucosinolates and the macamides and macaenes. 
The first group is typical of Brassicaceae; in maca, the 
main forms are aromatic glucosinolates [7], suggested 
by some authors as chemical markers to explain some 
biological effects of this plant [8] and denied by others. 
Over the last few years, different studies that have 
focused on the analysis and purification of macamides 
from this plant have been available in the literature. To 
this aim, lipophilic extracts of roots, such as those by 
petroleum ether [9] or by n-hexane [10], were selected. 
 Nevertheless, Ganzera et al. [11] highlighted, using high 
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performance liquid chromatography (HPLC), the pres-
ence of some macamides also in root powder methanol 
extract. Because the macamides have not been found in 
other Lepidium species, they have been proposed as phy-
tochemical markers of maca [10]. Recently, it has been 
highlighted that some aromatic glucosinolates, abundant 
in fresh roots, consistently decrease in the dried material 
because they are involved in the ex novo biosynthesis of 
macamides, together with free fatty acids [12].
Maca extracts are used for the treatment of a wide 
range of pathological conditions such as sexual infertility, 
osteoporosis, and benign prostatic hyperplasia [13, 14]. On 
the contrary, limited evidence of efficacy against persistent 
pain has been described up to now [15]. However, in vitro 
studies confirmed macaenes family components’ involve-
ment in enhancing cannabinoid transmission [16]. The cho-
linergic stimulation induced by L. meyenii extract (mainly 
by polyphenols) has been related to memory improvement 
[17] as well as antioxidant properties that may sustain the 
antidepressant-like effects of the plant extract [18]. More-
over, maca improves the antioxidant cell machinery [19]. 
Cannabinoid and cholinergic systems [20,  21], as well as 
redox unbalance [22–25], play a relevant role in persistent 
pain processes. Maca consumption has been associated 
with lower serum levels of the proinflammatory and pro-
algic cytokine IL-6 in populations living in the Peruvian 
Central Andes [8]. Starting from the theoretical approach 
that maca is able to modulate endogenous systems normally 
involved in pain control, the aim of this study was to evalu-
ate the efficacy, after acute intake (oral administration), of 
a commercial water extract of L. meyenii, controlled in its 
composition by high performance liquid chromatography 
with diode array detector (HPLC-DAD) and high perfor-
mance liquid chromatography-mass spectrometry (HPLC-
MS). The study was carried out in rat or mouse models of 
persistent pain induced by the intra-articular injection of 
monoiodoacetate (MIA), chronic constriction injury (CCI) of 
the sciatic nerve and chemotherapy-induced neuropathy.
2   Materials and methods
2.1   Sample preparation
The dried extract was purchased from KOS Spa, Italy, and 
was obtained from the roots of maca (L. meyenii Walp.) 
harvested in the Peruvian highlands in South America. 
According to the supplier’s documentation, the extract 
was obtained by water extraction, and to achieve a final 
powdered homogeneous sample, maltodextrins were 
added, obtaining a final 4:1 ratio of dry extract/excipient. 
Further technical specifications were not available from 
the supplier. This sample was fractionated as described 
subsequently: 50 mg of powder were dissolved in 1 mL of 
water (W) or acetonitrile/methanol (AM) 1:1 v/v; after 1 h 
of stirring, the solid residues were removed by centrifu-
gation and the solutions recovered to obtain W and AM 
extracts, respectively. These samples were then analyzed 
by HPLC-MS and tandem mass spectrometry (MS-MS).
2.2   HPLC-MS and MS-MS analysis
The HPLC-MS analyses were done using a Platin Blue 
UHPLC (Knauer, Germany) directly coupled to a 6410B 
triple quadrupole mass spectrometer (Agilent Technolo-
gies, USA) through an ESI interface. Two different columns 
were used: a Gemini C18 150 × 2  mm, 3 μm, 110 Å, and a 
Kinetex HILIC 150 × 2.1 mm, 2.6 μm, 100 Å (Phenomenex, 
Italy). For each column, a multistep linear gradient elution 
method was applied, in both cases using a 0.1% formic acid 
solution (eluent A) and acetonitrile, containing 0.1% formic 
acid (eluent B). The elution programs for the two columns 
are reported in the Supplementary information Table S1.
At the end of the run, the columns were re-equilibrated 
at the starting condition for 10 min. The injection volume 
was 10 μL; the column oven temperature was 30 °C. The 
diode-array UV detector recorded the full UV spectra in 
the range 210–500 nm, and the 240, 280 and 330 nm wave-
lengths. MS acquisitions were performed in scan mode 
(100–800  m/z scan range at 650  ms scan−1), switching 
between positive and negative polarities. The ESI inter-
face parameters were: nebulizer gas 30 psi, gas flow 10 L 
min−1, gas temperature 310 °C, capillary voltages 4.2 kV and 
4.0 kV in positive and negative modes, respectively.
2.3   Animals
Male Sprague-Dawley rats (Envigo, Varese, Italy) weigh-
ing approximately 200–250 g and male Swiss albino mice 
(Envigo, Varese, Italy) weighing approximately 23–25 g at 
the beginning of the experimental procedure were used. 
Animals were housed in CeSAL (Centro Stabulazione 
Animali da Laboratorio, University of Florence) and used 
at least 1 week after their arrival. Four rats and five mice 
were housed per cage (size 26–41 cm); animals were fed 
with standard laboratory diet and tap water ad libitum, 
and kept at 23 °C ± 1 °C with a 12-h light/dark cycle, light at 
7 a.m. All animal manipulations were carried out accord-
ing to Directive 2010/63/EU of the European parliament 
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and of the European Union council (22 September 2010) 
on the protection of animals used for scientific purposes. 
The ethical policy of the University of Florence complies 
with the Guide for the Care and Use of Laboratory Animals 
of the U.S. National Institutes of Health (NIH Publication 
No. 85-23, revised 1996; University of Florence assurance 
number: A5278-01). Formal approval to conduct the exper-
iments described was obtained from the Italian Ministry 
of Health (No. 54/2014-B) and from the Animal Subjects 
Review Board of the University of Florence. Experiments 
involving animals have been reported according to 
ARRIVE guidelines [26].
2.4   MIA-induced osteoarthritis
Unilateral osteoarthritis was also induced in rats by injec-
tion of MIA (Sigma-Aldrich, Italy) into the knee joint 
according to a described method [27, 28]. Exactly 2 mg MIA 
in 25 μL saline was delivered into the left articular cavity. 
Control rats received 25 μL of saline solution (day 1) in the 
knee joint. Behavioral and biochemical measures were 
performed on day 14.
2.5   CCI-induced neuropathy
Neuropathy was induced in rats according to a proce-
dure described by Bennett and Xie [29]. Another group of 
rats were subjected to sham surgery in which the sciatic 
nerve was only exposed but not ligated. The animals were 
allowed to recover from surgery and then housed one per 
cage with free access to water and standard laboratory 
chow. Behavioral tests were performed on day 14.
2.6   Oxaliplatin-induced neuropathy
Mice were treated with 2.4 mg kg−1 oxaliplatin, adminis-
tered i.p. for five consecutive days every week for 2 weeks 
(10 i.p. injections) [30, 31]. Oxaliplatin was dissolved in 
5% glucose solution. Control animals received an equiva-
lent volume of vehicle. Behavioral tests were performed 
on day 14.
2.7   Paclitaxel-induced neuropathy
Mice were treated with 2.0 mg kg−1 paclitaxel, administered 
i.p. four times on alternating days 1, 3, 5, and 7. Paclitaxel 
was dissolved in 10% Cremophor E-L of saline solution 
[32]. Control animals received an equivalent volume of 
vehicle. Behavioral and biochemical tests were performed 
on day 14.
2.8   Maca extract administration
Maca extract (KOS Spa, Italy) was suspended in 1% car-
boxymethylcellulose sodium salt and administered orally. 
Acute administrations (0.5, 1.5, 3 and 10 g kg−1; conven-
tionally, 1 kg was considered as corresponding to 10 mL) 
were performed on day 14 after damage induction (CCI 
and MIA) or anticancer drug treatment start (oxaliplatin 
and   paclitaxel). Behavioral tests were performed before 
and over time (60 min) after maca extract administration.
2.9   Paw pressure test
The nociceptive threshold in the rat was determined with 
an analgesimeter (Ugo Basile, Varese, Italy), according to 
a method described by Leighton et al. [33]. Rats scoring 
less than 40 g or more than 75 g during the test before 
drug administration were rejected (25%). For analgesia 
measures, mechanical pressure application was stopped 
at 120 g.
2.10   Incapacitance test
Weight-bearing changes were measured using an incapac-
itance apparatus (Linton Instrumentation, UK) detecting 
changes in postural equilibrium after a hind limb injury 
[34]. Rats were trained to stand on their hind paws in a box 
with an inclined plane (65° from horizontal). The value 
considered for each animal was the mean of five consecu-
tive measurements. Data are expressed as the difference 
between the weight applied on the limb contralateral to 
the injury and the weight applied on the ipsilateral one 
(ΔWeight).
2.11   Cold plate test
The animals (mice) were placed in a stainless steel box 
(12 cm × 20 cm × 10 cm) with a cold plate as floor. The tem-
perature of the cold plate was kept constant at 4 °C ± 1 °C. 
Pain-related behaviors (i.e. lifting and licking of the hind 
paw) were observed and the time(s) of the first sign was 
recorded. The cutoff time of the latency of paw lifting or 
licking was set at 60 s [35].
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2.12   Rotarod test
The rotarod apparatus for rats (Ugo Basile, Varese, Italy) 
consisted of a base platform and a rotating rod with a 
diameter of 6 cm and a nonslippery surface. The rod was 
placed at a height of 25 cm from the base. The rod, 36 cm 
in length, was divided into four equal sections using five 
disks. Thus, up to four rats were tested simultaneously on 
the apparatus, with a rod-rotating speed of 10  rpm. The 
integrity of motor coordination was assessed on the basis 
of the number of falls from the rod in 30 s. Those animals 
scoring less than three and more than six falls in the 
pretest were rejected. The performance time was meas-
ured every 15  min for four times. Animals with normal 
coordination progressively reduced the number of falls 
during the experimental sessions.
2.13   Statistical analysis
Results were expressed as means ± SEM and the analy-
sis of variance was performed by ANOVA test. A Bonfer-
roni’s significant difference procedure was used as a post 
hoc comparison. P values less than 0.05 were considered 
significant. Data were analyzed using the “Origin 8.1” 
software.
3   Results
Several analytical methods were proposed to investigate 
macamides [11] and glucosinolates [7] recognized as the 
main bioactive phytochemicals of maca. According to 
these findings, the aim of this work was to check the pres-
ence of these two groups of molecules in the commer-
cial extract selected for this in vivo study. The screening 
was done by HPLC-DAD-MS working on two extracts, at 
different polarities, obtained from the same commercial 
sample. The chromatographic profiles of the W extract 
on the Gemini® column did not reveal the presence of 
analytes detectable in the 220–330  nm range. The same 
test on the HILIC column, specifically selected to high-
light the glucosinolates, confirmed the absence of these 
compounds and the presence of several diglycosides and 
oligoglycosides, as expected. On the contrary, the AM 
extract after the HPLC-DAD-MS screening in positive and 
negative ionization mode, showed the best result in posi-
tive mode. By LC-MS several macamides were detected by 
their intense [M + H]+ and/or [M + Na]+ ions. Supplemen-
tary Figure S1A shows the base peak chromatogram in the 
300–450 m/z range, selected in agreement with a recent 
article focused on the comparison of macamides in differ-
ent batches of maca hypocotyls [9]. To summarize, some 
representative extract ion profiles at the selected masses 
are reported in Supplementary Figure S1B, whereas all the 
detected macamides are listed in Table 1.
The DAD profile also allowed us to point out a group 
of lipophilic metabolites with retention time values close 
to that of macamides and characterized by their UV-Vis 
spectra and ion molecular weight as reported in Supple-
mentary Figure S2. To date, further information is not 
available on these compounds.
The pain reliever effect of L. meyenii extract was eval-
uated in several models of persistent pain by behavioral 
tests. In Figure 1, the effect of MIA administration in rats 
is shown. Fourteen days after MIA injection, the paw pres-
sure test lead us to appreciate that the weight tolerated 
on the ipsilateral paw was significantly reduced com-
pared with the contralateral (data not shown). A total of 
10 g kg−1 of L. meyenii extract time dependently reduced 
MIA-evoked mechanical hypersensitivity increasing the 
weight tolerated up to 70.8 ± 2.2 g (Figure 1A). Figure  1B 
shows the difference between the weight burdened on 
the contralateral and the ipsilateral limb. ΔWeight was 
 significantly increased in MIA + vehicle-treated rats 
Table 1: List of the detected macamides in the AM extract of L. meyenii in positive ion mode and potential identification.
Rt (min)   [M + H]+ 
(% intensity)
  [M + Na]+ 
(% intensity)
  Identity
42.20   384 (5)  406 (95)  N-Benzyl-9-oxo-(12Z, 15Z)-octadecadienamide
42.36   384 (5)  406 (95)  N-Benzyl-13-oxo-(9E, 11E)-octadecadienamide
42.54   386 (5)  408 (95)  N-Benzyl-9-oxo-12Z-octadecanamide
43.09   368 (80)  390 (20)  N-Benzyl-13-oxo-(9Z, 12Z, 15Z)-octadecatrienamide
43.61   370 (100)  –  N-Benzyl-(9Z, 12Z)-octadecadienamide
44.20   346 (50)  368 (50)  N-Benzyl-hexadecanamide
44.29   372 (80)  394 (20)  N-Benzyl-9Z-octadecanamide
42.88   374 (100)  –  N-Benzyl-octadecanamide
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(67.6 ± 1.6 g) in comparison to vehicle + vehicle-treated rats 
(5.0 ± 1.5 g). Lepidium meyenii (10 g kg−1) was able to statisti-
cally reduce hind limb weight-bearing alterations peaking 
15  min after treatment (41.1 ± 6.0 g). Lepidium meyenii 
extract was also effective on neuropathic pain induced in 
rats by lesion to the peripheral nervous system. Rat paw 
pressure test revealed that 14  days after CCI, the weight 
tolerated on the ipsilateral paw significantly decreased 
(43.3 ± 3.3 g) with respect to the contralateral (68.3 ± 3.1 g) 
(data not shown). As depicted in Figure 2A, 10  g  kg−1 of 
L. meyenii completely reverted the CCI-induced hyperalge-
sia for 30 min after administration. Moreover, the effect of 
the extract was also evaluated by measuring spontaneous 
pain of CCI rats with the incapacitance test. As shown in 
Figure 2B, 10 g kg−1 of L. meyenii extract reduced the dif-
ference between the weight burdened on the contralateral 
and the ipsilateral limb by approximately 45%. A differ-
ent kind of neuropathic pain was induced in mice by the 
administration of the neurotoxic drugs oxaliplatin and 
paclitaxel. The platin-derivative anticancer compound 
was repeatedly administered and, on day 14, it induced a 
lowered threshold to cold stimuli that was measured by 
cold plate test (Figure  3A the licking latency of oxalipl-
atin + vehicle-treated mice is 11.6 ± 0.7  s vs. 21.2 ± 1.2  s of 
vehicle + vehicle-treated mice). Lepidium meyenii extract, 
acutely administered in a dose range of 0.5–10 g kg−1, 
reverted oxaliplatin-induced neuropathic pain in a dose-
dependent manner. A total of 10 g kg−1 evoked the longest 
significant effect peaking 30  min after administration 
(20 ± 0.9 s). Moreover, 3 and 1.5 g kg−1 induced a statisti-
cally significant effect. In Figure 3B, the effect of repeated 
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Figure 1: Articular pain.
On day 14 after MIA injection, L. meyenii extract (10 g kg−1) was 
p.o. administered and pain threshold was evaluated over time. 
(A) Response to a noxious mechanical stimulus evaluated by paw 
pressure test on the ipsilateral paw. (B) Hind limb weight-bearing 
alterations were measured by incapacitance test. n = 10; *P < 0.01 
versus vehicle + vehicle-treated rats; ^P < 0.05 and ^^P < 0.01 
versus MIA + vehicle-treated rats.
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Figure 2: CCI-induced neuropathic pain.
On day 14 after nerve surgery, L. meyenii extract (10 g kg−1) was 
p.o. administered and pain threshold was evaluated over time. 
(A) Response to a noxious mechanical stimulus evaluated by paw 
pressure test on the ipsilateral paw. (B) Hind limb weight-bearing 
alterations were measured by incapacitance test 14 days after 
surgery. n = 10; **P < 0.01 versus vehicle + vehicle-treated rats; 
^P < 0.05 and ^^P < 0.01 versus CCI + vehicle-treated rats.
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paclitaxel administrations in mice is shown. On day 14, 
the taxane derivative decreased the time that animals 
tolerate on a cold surface (11.5 ± 0.9 s, paclitaxel + vehicle 
vs. 23.4 ± 1.7 s, vehicle + vehicle). Lepidium meyenii extract 
was administered at a dose range of 0.5–10 g kg−1. As 
depicted in Figure 3B, 0.5, 1.5, and 3 g kg−1 doses induced 
a significant effect, whereas the highest dose significantly 
increased licking latency peaking (21.6 ± 1.6  s) 30  min 
after the administration. Table 2 displays the effect of the 
maximum tested dose of L. meyenii (10 g kg−1) on animals’ 
motor coordination as evaluated by rotarod test. Fifteen 
minutes after extract administration, the animals were 
placed on the rotating rod (10  rpm) for 10  min and the 
number of falls was counted. Administration of L. meyenii 
extract did not induce significant alterations of motor 
coordination in comparison with the control group.
4   Discussion
The present results describe the pain-relieving effects 
of an aqueous extract of L. meyenii, in three different 
models of persistent pain. In particular, the intra-articu-
lar injection of MIA provides a monolateral osteoarthritis 
characterized by a persistent inflammatory pain which, 
starting on day 14 after injection, possesses a neuropathic 
component [36]. Ten gram per kilogram of maca extract 
reduces pain induced by a mechanical noxious stimu-
lus on the ipsilateral paw. Moreover, maca-dependent 
pain relief allows also to reduce postural unbalance, 
an outward of osteoarthritis progression, as measured 
by hind limb weight bearing alterations [34]. The anti-
neuropathic properties of the L. meyenii extract are con-
firmed after the ligation of the sciatic nerve, a neuropathy 
model where the alterations of the nerve morphology are 
accompanied by remarkable inflammatory state emerged 
in terms of cellular infiltrate and edema [37, 38]. Maca 
extract, at maximum dosage, is able to revert mechanical 
hypersensitivity for 30 min, after injection, as shown by 
paw pressure test. Ten gram per kilogram of L. meyenii 
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Figure 3: Chemotherapy-induced neuropathic pain.
(A) Oxaliplatin-induced neuropathic pain. Mice were treated i.p. 
daily with 2.4 mg kg−1 oxaliplatin. (B) Paclitaxel-induced neuropathic 
pain. Mice were treated i.p. (on days 1, 3, 5, and 7) with 2 mg kg−1 
paclitaxel. The response to a thermal non-noxious stimulus was 
evaluated by cold plate test. Behavioral test was performed on day 
14. Before and after L. meyenii extract (0.5–10 g kg−1) p.o. admin-
istration. n = 10; *P < 0.05 versus vehicle + vehicle; ^P < 0.05 and 
^^P < 0.01 versus oxaliplatin + vehicle; ^P < 0.05 and ^^P < 0.01 
versus paclitaxel + vehicle.
Table 2: Effect of L. meyenii extract on mouse motor coordination (rotarod test).
Treatment   Dosage 
(g kg−1)
 
 
Falls number (min)
0  15  30  45  60
Vehicle     7.0 ± 0.8  5.0 ± 1.0  1.0 ± 0.2  1.0 ± 0.4  0.0 ± 0.0
Lepidium meyenii   10  5.3 ± 1.3  2.0 ± 1.0  0.6 ± 0.3  1.6 ± 0.3  0.0 ± 0.0
Animals received L. meyenii extract (10 g kg−1) per os; 15 min (time 0) after the administration they were placed on the rotating rod (10 rpm) for 
30 s and the number of falls was evaluated. The performance time was measured every 15 min to evaluate the ability of the animals to acquire the 
movement. Each value represents the mean ± SEM of eight rats per group, performed in two different experimental sets. P > 0.05 between groups.
Brought to you by | Università degli Studi di Firenze
Authenticated
Download Date | 1/15/18 4:02 PM
Tenci et al.: Pain-relieving effect of a maca extract      455
significantly reduces the postural unbalance induced by 
the nerve ligation as revealed by the incapacitance test. 
Our results also demonstrate that a single oral adminis-
tration of maca extract (10 g kg−1) is able to completely 
revert the thermal allodynia induced in mice after oxali-
platin or paclitaxel chronic treatment. The platinum 
and the taxane derivatives are used for treatment of 
several types of cancer as colorectal cancer, lung cancer 
or ovarian cancer [39, 40]. Their chronic administration 
causes a peripheral neuropathy characterized by hyper-
sensitivity to cold stimuli [41, 42]. These models of neuro-
pathic pain are free from inflammatory components and 
are characterized by specific molecular alteration of the 
peripheral and central nervous system [35]. The mainte-
nance of efficacy in these different kinds of pain suggests 
an interesting pharmacodynamic profile. The dosages 
used are quite high but compatible with the use as food 
supplement. Furthermore, no signs of evident toxicity 
are highlighted in all treatment groups; in particular, 
as shown by the rotarod test performances, no motor or 
neurological alteration was detectable. This maca sample 
was obtained using an aqueous extraction of the root, as 
declared in the label, and consequently was not rich in 
lyphophilic components. Nevertheless, the high sensi-
tivity of a mass spectrometer, differently from the DAD, 
allowed to detect the unexpected presence of several 
macamides tentatively identified according to their mole-
cular weight [9].
Furthermore, by use of the HILIC column, suitable 
to analyzing very polar compounds, the absence of glu-
cosinolates in our sample was confirmed. This finding 
is in agreement with a recent work that correlates the 
low content of glucosinolates in dried maca roots to the 
increase of macamides after the drying process. The 
hydrolytic phenomena associated with open-air drying 
are responsible of the formation of the precursors of 
macamides, which continue to be synthetized until a 
water content close to 13% is achieved [12]. Even if in low 
amounts, the macamides can contribute to the observed 
effect in rats.
At the end, it is worth noting the presence of a group 
of unknown metabolites with UV-Vis spectra indicat-
ing a chromophoric system that can indicate a possible 
antioxidant capacity that can contribute to the biological 
effects of this commercial maca sample. At the same time, 
the shape of these spectra did not confirm the presence 
of typical flavonoids or flavones, some of them previ-
ously found in maca. In vitro studies have demonstrated 
that macaenes and macamides are able to inhibit the 
FAAH enzyme, normally responsible for inactivation of 
anandamide, the main endogenous endocannabinoid. 
Anandamide is involved in several physiological pro-
cesses such as painful sensitivity and neuroprotection 
[16]. Selective FAAH inhibitors enhance anandamide 
endogenous levels that cause antinociceptive effect by 
agonism on the CB2 receptor [21]. Furthermore, many 
preclinical studies demonstrated that FAAH inhibitors 
reduce chronic pain without the development of toler-
ance after repeated administrations [43]. The absence of 
flavonoids in the present extract was confirmed by the 
investigation on the UV-vis and mass spectra registered, 
respectively, by HPLC-DAD and by MS at different frag-
mentation energies. Only a recent work cited two new 
flavolignans [44]. By the mass experiments, it was pos-
sible to exclude the presence of these compounds in our 
extract. At the same time, other known phenolic com-
pounds were also reported in the same work, as pinores-
inol and tricine were not detected. These results strongly 
suggest the exclusion of both cholinergic system modu-
lation and antioxidant effects of phenolic compounds 
from the pharmacodynamic mechanisms. The absence 
of the glucosinolates, confirmed by mass spectrometric 
analyses, allowed us to exclude the contribution of these 
phytochemicals for the biological effect observed for the 
maca extract.
In conclusion, L. meyenii extract is effective as a pain 
reliever in different models of persistent pain, both in 
those with a predominant inflammatory component and 
in those with a predominant neuropathic aspect. The 
absence of evident toxicity, confirmed by its common 
use as a customary refreshment as well as a traditional 
remedy by Peruvian people, shows that L. meyenii extract 
is a possible treatment against osteoarticular and neuro-
pathic pain.
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